NRX Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by NRX Pharmaceuticals, Inc. (NRXP) on November 18, 2024. The filing discloses the appointment of a new Chief Financial Officer and the execution of a material definitive employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of Michael Abrams as Chief Financial Officer, effective November 18, 2024. He succeeds Interim CFO Richard Narido, who will remain to support the transition.
Employment Agreement and Compensation Details
- Base Salary: $325,000 annually. During an initial period (until the earlier of a Qualified Financing or February 1, 2025), the salary is reduced to 50% of the base amount.
- Equity Grant: 50,000 stock options vesting over three years. The exercise price will be set at the closing stock price on the date of a Qualified Financing.
- Bonus: Annual discretionary bonus of up to 40% of the Base Salary.
- Severance:
- Termination without Cause within 3 months: 60 days of Base Salary.
- Termination without Cause after 3 months: Base Salary for 3 months plus 1 month for every 2 months of employment thereafter, capped at 6 months total. Includes immediate vesting of unvested equity.
Investor Verification Checklist
- Verify the definition and conditions of a "Qualified Financing" required to trigger full salary and option pricing.
- Confirm the current cash position of the company to assess the ability to fund the new executive compensation package.
- Review the status of the transition from Interim CFO Richard Narido.
- Check for any pending financing activities that may impact the option exercise price.